Clinical Research Directory

Inclusion Criteria: 1. Patients with flat- type BE esophagus, with an indication for ablation therapy, defined as: * Diagnosis of LGD or HGD in BE (confirmed by central pathology review), OR * Residual BE with any grade of dysplasia 6 weeks after endoscopic resection 2. Prague Classification Score C≤3 and ≥M1 3. Patients should be ablation-naïve (no previous ablation therapy of the esophagus) 4. Older than 18 years of age at time of consent 5. Operable per institution's standards 6. Patient provides written informed consent on the IRB-approved informed consent form 7. Patient is willing and able to comply with follow-up requirements. Exclusion Criteria: 1. Esophageal stenosis preventing advancement of a therapeutic endoscope 2. Any endoscopically visualized lesion such as ulcers, masses or nodules. Neoplastic nodules must first be treated with ER ≥6 weeks prior to planned treatment under this protocol. 3. Prior ER of more than 2cm in length and/or \>50% of the esophageal lumen circumference 4. History of locally advanced (\>SM1) esophageal cancer 5. History of esophageal varices 6. Prior distal esophagectomy 7. Active esophagitis LA grade B or higher 8. Severe medical comorbidities precluding endoscopy 9. Uncontrolled coagulopathy 10. Pregnant or planning to become pregnant during period of study 11. Patient refuses or is unable to provide written informed consent 12. Participation in another study with investigational drug within the 30 days preceding or during the present study, interfering with participation in the current study 13. General poor health, multiple co-morbidities placing the patient at risk or otherwise unsuitable for trial participation